Condition

Duloxetine clinical trials and research

As of November 12, 2026, Find a Trial lists 4 Duloxetine clinical trials that are recruiting, at sites in 4 countries (most in Egypt (1), United States (1), Brazil (1)). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.

Newest Duloxetine clinical trials

StudyPhaseWhereStatusRegistered
Amantadine or duloxetine added to pregabalin to prevent post-mastectomy pain — Cairo Recruiting Feb 19, 2026
Pregabalin combined with toludesvenlafaxine for fibromyalgia pain — Beijing Recruiting Oct 6, 2025
Home-based brain stimulation versus duloxetine for fibromyalgia — Porto Alegre, Rio Grande do Sul Recruiting Oct 2, 2025
Understanding how duloxetine works for fibromyalgia — Salt Lake City, Utah Recruiting Mar 10, 2025

All recruiting trials (4)

Related topics

FibromyalgiaPregabalinBDNFEEGFibromyalgia (FM)MastectomyPain SyndrometDCS

Quick answers

How many Duloxetine clinical trials are recruiting right now?

4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 4 countries. The most sites are in Egypt (1 trial), United States (1 trial), Brazil (1 trial), China (1 trial). Each study page lists its sites and which ones are recruiting.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →

Last reviewed 2026-11-12 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.